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Purpose or Objective: To assess and validate the 
incorporation of the multiparametric magnetic resonance 
imaging (mpMRI) tumor stage (mT-stage) to the conventional 
clinical tumor stage (cT-stage), in order to guide the 
radiotherapy (RT) treatment decisions in prostate cancer. In 
addition, to identify the clinical factors associated to the 
technique reliability.  
 
Material and Methods: mpMRI was performed in 274 prostate 
cancer patients in order to refine the treatment decisions 
according to PSA, Gleason Score (GS) and cT-stage. 
Comparisons between the cT and mT-stage were performed, 
as well as the impact on the RT treatment prescription 
(target volume, doses and hormonal therapy [HT]) 
independently if it was finally performed. Changes in HT 
indication for intermediate risk with unfavourable factors 
were also analyzed. Until 2014, the unfavourable factors 
according to the initial criteria were a GS of 7 (4+3), or three 
unfavourable intermediate risk factors (T2b+PSA 10-20 ng/mL 
+ GS 3+4), or T2c by digital rectal exam (DRE)/transrectal 
ultrasound (TRUS); more recently, unfavourable risk factors 
have been established according to Memorial Sloan Kettering 
Cancer Center (MSKCC) criteria: GS 4+3, or at least two 
intermediate-risk factors, or at least one intermediate-risk 
factor and a positive prostate biopsies (ppb) percentage 
greater than 50%. mpMRI validation was performed with 
pathological staging (n=90 patients finally decided to join 
surgery). To analyse the relationship between the reliability 
of mpMRI and the clinical variables, a univariate and 
multivariate logistic regression analysis was performed. 
 
Results: The mpMRI upstaging range was 86-94% for any PSA 
value or GS. Following mpMRI, 32.8% of the patients (90/274) 
were assigned to a different risk group. Compared to cT-
stage, mpMRI identified more intermediate-risk (46.4% vs. 
59.5%) and high-risk (19.0% vs. 28.8%) prostate cancer 
patients. This resulted in a higher indication (p<0.05) of 
seminal vesicle irradiation (63.5% vs. 70.1%), inclusion of any 
extracapsular disease (T3-T4) within the target volume (1.8% 
vs. 18.2%), higher doses (65.3% vs. 88.3%) and more 
indication of HT associated to RT (45.6% vs. 62.4%), Table 1. 
Finally, decisions concerning RT were changed in 43.8% 
(initial criteria) or 52.5% (MSKCC criteria) of the patients, 
depending on the criteria applied to indicate HT in 
intermediate-risk patients. Global reliability of T-staging with 
DRE/TRUS was 8.8% (8/90), while it was 71.1% (64/90) for 
mpMRI. cT-stage was associated to a greater occurrence 
(p<0.05) of indication of inadequate RT treatments. mpMRI 
reliability was independent of PSA or GS or ppb percentage.  
 
 
Conclusion: mpMRI tumor staging significantly improved the 
RT treatment decisions in all prostate cancer risk groups. The 
magnitude of the impact on final RT treatment decisions will 
depend on the institution’s clinical protocol for prostate 
cancer management. 
 
PO-0737  
Predictors of PSA relapse in patients with intermediate risk 
prostate cancer treated with SBRT 
T. Kole
1Georgetown University Hospital, Radiation Medicine, 
Washington, USA 
1, S. Guleria1, H. Koneru1, O. Obayomi-Davies1, T. 
Yung1, S. Lei1, B. Collins1, S. Suy1, A. Dritschilo1, S. Collins1 
 
Purpose or Objective: SBRT has demonstrated favorable 
outcomes in selected patients with early stage localized 
prostate cancer. Treatment of patients with intermediate 
risk disease remains cautionary due to the heterogeneity 
within this population with respect to risk for occult 
extraprostatic disease. Here we report an analysis of PSA 
outcomes following SBRT for intermediate risk prostate 
cancer and identify disease specific risk factors for 
biochemical failure. 
 
Material and Methods: Patients treated with SBRT at 
Georgetown University Hospital for intermediate risk prostate 
adenocarcinoma, with or without the use of androgen 
deprivation therapy (ADT), were included in this 
retrospective analysis. Treatment was delivered using 
CyberKnife® SBRT with doses of 35 Gy or 36.25 Gy in 5 
fractions. PSA failure was defined as a rise > 2 ng/ml above 
nadir (ASTRO Phoenix definition) and analyzed using the 
Kaplan Meier method. A Cox proportional hazards model was 
generated using disease related covariates including T stage, 
primary gleason pattern, pretreatment PSA, number of 
positive cores, percent positive cores, maximum single core 
involvement in order to identify potential predictors of PSA 
relapse after SBRT. A logrank test was also used to compare 
patients classified as having favorable vs. unfavorable 
intermediate risk disease by previously reported criteria of 
primary gleason pattern 4, ≥ 50% cores involved, or ≥2 
intermediate risk factors. 
 
Results: Three hund;red and fifty three patients at a median 
age of 70 years (range, 46 to 90) received SBRT. ADT was 
initiated prior to SBRT in 16% of patients and the median pre-
